Autolus Therapeutics plc
AUTLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Autolus Therapeutics plc focuses on Biotechnology services and products. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company carries a $383.2M market cap, placing it firmly in the small-cap category. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Market Cap
$383.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.38
EPS (TTM)
$-1.08
EPS (Fwd)
$-0.61
ROE
-29.6%
ROA
-22.3%
Cash
$217.4M
Total Debt
$0
Free CF
—
52W Change
-40.3%
Annual Financials
Cash vs Debt
Autolus Therapeutics plc reports $217.4M in cash and $0 in total debt. Return on equity stands at -29.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $6.2M (2022) to $75.4M (2025), reflecting a 1117% increase over the period.
Investors considering Autolus Therapeutics plc should weigh the typical risks associated with AUTL's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Autolus Therapeutics plc's trajectory.